^
Association details:
| Biomarker: | ALK rearrangement + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) + Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Tolerability of ALK/ MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis
Published date:
08/03/2023
Excerpt:
We assembled a cohort of patients with ALK+ lung cancer and acquired MET amplification (identified by tissue or plasma) who received regimens targeting both ALK and MET....Partial responses were observed in five (42%) of 12 patients, including patients who received crizotinib (n = one of two), lorlatinib plus crizotinib (n = three of six), and alectinib plus capmatinib (n = one of three).
DOI:
10.1016/j.jtocrr.2023.100534
